Old Web
English
Sign In
Acemap
>
authorDetail
>
Mathew John Joseph
Mathew John Joseph
Seattle Children's Research Institute
Medicine
Oncology
Internal medicine
Bevacizumab
Physical therapy
4
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Impact of community practice on providing in-patient oncology and hematology consults via telemedicine to remote rural hospital.
2019
Journal of Clinical Oncology
Natalie R. Dickson
Larry Edward Bilbrey
Mathew John Joseph
Janet A Matheny
Stacey L Poole
Jeffrey Patton
Show All
Source
Cite
Save
Citations (1)
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non–small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2
2018
Cancer
David R. Spigel
John D. Hainsworth
Mathew John Joseph
Dianna Shipley
M. Kelly Hagan
Dana S. Thompson
Howard A. Burris
F. Anthony Greco
Show All
Source
Cite
Save
Citations (9)
Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
2017
Journal of Clinical Oncology
David Waterhouse
John D. Hainsworth
F. A. Greco
Edward K. Barnes
Christopher F. Lobo
Victor G. Gian
Mathew John Joseph
James D. Peyton
Sang Y. Huh
D. Daniel
Raven Quinn
Howard A. Burris
David R. Spigel
Show All
Source
Cite
Save
Citations (1)
A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC).
2015
Journal of Clinical Oncology
Mathew John Joseph
Kirk Barnes
Ronald Blachly
Michel E. Kuzur
J. C. Bendell
Show All
Source
Cite
Save
Citations (1)
1